Filing Details
- Accession Number:
- 0001104659-23-079663
- Form Type:
- 13G Filing
- Publication Date:
- 2023-07-09 20:00:00
- Filed By:
- Venrock Healthcare Capital Partners Iii, L.p.
- Company:
- Spyre Therapeutics Inc. (NASDAQ:SYRE)
- Filing Date:
- 2023-07-10
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Partners III | 0 | 7,980,000 | 0 | 7,980,000 | 7,980,000 | 9.99% |
| VHCP Co-Investment Holdings III | 0 | 7,980,000 | 0 | 7,980,000 | 7,980,000 | 9.99% |
| Venrock Healthcare Capital Partners EG | 0 | 7,980,000 | 0 | 7,980,000 | 7,980,000 | 9.99% |
| VHCP Management III | 0 | 7,980,000 | 0 | 7,980,000 | 7,980,000 | 9.99% |
| VHCP Management EG | 0 | 7,980,000 | 0 | 7,980,000 | 7,980,000 | 9.99% |
| Shah, Nimish | 0 | 7,980,000 | 0 | 7,980,000 | 7,980,000 | 9.99% |
| Koh, Bong | 0 | 7,980,000 | 0 | 7,980,000 | 7,980,000 | 9.99% |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
Aeglea BioTherapeutics, Inc.
(Name of Issuer)
Common Stock, $0.0001 Par Value Per Share
(Title of Class of Securities)
00773J103
(CUSIP Number)
June 28, 2023
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨
x
¨ | Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d) |
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 00773J103 | Page 2 of 24 |
| 1. | Names of Reporting Persons
Venrock Healthcare Capital Partners III, L.P. |
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)
(a) x (1) (b) ¨ |
| 3. | SEC Use Only
|
| 4. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With | 5. | Sole Voting Power
0 |
| 6. | Shared Voting Power
7,980,000 (2) | |
| 7. | Sole Dispositive Power
0 | |
| 8. | Shared Dispositive Power
7,980,000 (2) |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
7,980,000 (2) |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
|
| 11. | Percent of Class Represented by Amount in Row (9)
9.99% (3) |
| 12. | Type of Reporting Person (See Instructions)
PN |
| (1) | Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G. |
| (2) | Consists of (i) 1,708,850 shares of common stock and 389,000 shares of common stock issuable upon conversion of Series A Preferred Stock at a conversion ratio of 1 share of Series A Preferred Stock to 1,000 shares of common stock (the “Series A Preferred Stock”) held by Venrock Healthcare Capital Partners III, L.P.; (ii) 170,950 shares of common stock and 39,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,620,200 shares of common stock and 1,052,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon conversion of the Series A Preferred Stock held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Securities Purchase Agreement dated as of June 22, 2023, the Issuer may not effect the conversion of any such Series A Preferred Stock and a holder will not be entitled to convert any portion of such Series A Preferred Stock, if, upon giving effect to such conversion, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the conversion. |
| CUSIP No. 00773J103 | Page 3 of 24 |
| (3) | This percentage is calculated based upon the sum of (i) 65,395,159 shares of common stock outstanding as of May 2, 2023 as reported in the Form 10-Q filed by the Issuer on May 11, 2023; (ii) 13,013,636 shares of common stock issued in connection with the merger transaction disclosed in the Issuer’s Current Report on Form 8-K filed on June 23, 2023; and (iii) 1,480,000 shares of common stock issuable upon the conversion of Series A Preferred Stock described in Footnote 2 above. |
| CUSIP No. 00773J103 | Page 4 of 24 |
| 1. | Names of Reporting Persons
VHCP Co-Investment Holdings III, LLC |
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)
(a) x (1) (b) ¨ |
| 3. | SEC Use Only
|
| 4. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With | 5. | Sole Voting Power
0 |
| 6. | Shared Voting Power
7,980,000 (2) | |
| 7. | Sole Dispositive Power
0 | |
| 8. | Shared Dispositive Power
7,980,000 (2) |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
7,980,000 (2) |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
|
| 11. | Percent of Class Represented by Amount in Row (9)
9.99% (3) |
| 12. | Type of Reporting Person (See Instructions)
OO |
| (1) | Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G. |
| (2) | Consists of (i) 1,708,850 shares of common stock and 389,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by Venrock Healthcare Capital Partners III, L.P.; (ii) 170,950 shares of common stock and 39,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,620,200 shares of common stock and 1,052,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon conversion of the Series A Preferred Stock held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Securities Purchase Agreement dated as of June 22, 2023, the Issuer may not effect the conversion of any such Series A Preferred Stock and a holder will not be entitled to convert any portion of such Series A Preferred Stock, if, upon giving effect to such conversion, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the conversion. |
| CUSIP No. 00773J103 | Page 5 of 24 |
| (3) | This percentage is calculated based upon the sum of (i) 65,395,159 shares of common stock outstanding as of May 2, 2023 as reported in the Form 10-Q filed by the Issuer on May 11, 2023; (ii) 13,013,636 shares of common stock issued in connection with the merger transaction disclosed in the Issuer’s Current Report on Form 8-K filed on June 23, 2023; and (iii) 1,480,000 shares of common stock issuable upon the conversion of Series A Preferred Stock described in Footnote 2 above. |
| CUSIP No. 00773J103 | Page 6 of 24 |
| 1. | Names of Reporting Persons
Venrock Healthcare Capital Partners EG, L.P. |
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)
(a) x (1) (b) ¨ |
| 3. | SEC Use Only
|
| 4. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With | 5. | Sole Voting Power
0 |
| 6. | Shared Voting Power
7,980,000 (2) | |
| 7. | Sole Dispositive Power
0 | |
| 8. | Shared Dispositive Power
7,980,000 (2) |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
7,980,000 (2) |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
|
| 11. | Percent of Class Represented by Amount in Row (9)
9.99% (3) |
| 12. | Type of Reporting Person (See Instructions)
PN |
| (1) | Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G. |
| (2) | Consists of (i) 1,708,850 shares of common stock and 389,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by Venrock Healthcare Capital Partners III, L.P.; (ii) 170,950 shares of common stock and 39,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,620,200 shares of common stock and 1,052,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon conversion of the Series A Preferred Stock held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Securities Purchase Agreement dated as of June 22, 2023, the Issuer may not effect the conversion of any such Series A Preferred Stock and a holder will not be entitled to convert any portion of such Series A Preferred Stock, if, upon giving effect to such conversion, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the conversion. |
| CUSIP No. 00773J103 | Page 7 of 24 |
| (3) | This percentage is calculated based upon the sum of (i) 65,395,159 shares of common stock outstanding as of May 2, 2023 as reported in the Form 10-Q filed by the Issuer on May 11, 2023; (ii) 13,013,636 shares of common stock issued in connection with the merger transaction disclosed in the Issuer’s Current Report on Form 8-K filed on June 23, 2023; and (iii) 1,480,000 shares of common stock issuable upon the conversion of Series A Preferred Stock described in Footnote 2 above. |
| CUSIP No. 00773J103 | Page 8 of 24 |
| 1. | Names of Reporting Persons
VHCP Management III, LLC |
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)
(a) x (1) (b) ¨ |
| 3. | SEC Use Only
|
| 4. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With | 5. | Sole Voting Power
0 |
| 6. | Shared Voting Power
7,980,000 (2) | |
| 7. | Sole Dispositive Power
0 | |
| 8. | Shared Dispositive Power
7,980,000 (2) |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
7,980,000 (2) |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
|
| 11. | Percent of Class Represented by Amount in Row (9)
9.99% (3) |
| 12. | Type of Reporting Person (See Instructions)
OO |
| (1) | Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G. |
| (2) | Consists of (i) 1,708,850 shares of common stock and 389,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by Venrock Healthcare Capital Partners III, L.P.; (ii) 170,950 shares of common stock and 39,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,620,200 shares of common stock and 1,052,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon conversion of the Series A Preferred Stock held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Securities Purchase Agreement dated as of June 22, 2023, the Issuer may not effect the conversion of any such Series A Preferred Stock and a holder will not be entitled to convert any portion of such Series A Preferred Stock, if, upon giving effect to such conversion, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the conversion. |
| CUSIP No. 00773J103 | Page 9 of 24 |
| (3) | This percentage is calculated based upon the sum of (i) 65,395,159 shares of common stock outstanding as of May 2, 2023 as reported in the Form 10-Q filed by the Issuer on May 11, 2023; (ii) 13,013,636 shares of common stock issued in connection with the merger transaction disclosed in the Issuer’s Current Report on Form 8-K filed on June 23, 2023; and (iii) 1,480,000 shares of common stock issuable upon the conversion of Series A Preferred Stock described in Footnote 2 above. |
| CUSIP No. 00773J103 | Page 10 of 24 |
| 1. | Names of Reporting Persons
VHCP Management EG, LLC |
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)
(a) x (1) (b) ¨ |
| 3. | SEC Use Only
|
| 4. | Citizenship or Place of Organization
Delaware |
Number of Shares Beneficially Owned by Each Reporting Person With | 5. | Sole Voting Power
0 |
| 6. | Shared Voting Power
7,980,000 (2) | |
| 7. | Sole Dispositive Power
0 | |
| 8. | Shared Dispositive Power
7,980,000 (2) |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
7,980,000 (2) |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
|
| 11. | Percent of Class Represented by Amount in Row (9)
9.99% (3) |
| 12. | Type of Reporting Person (See Instructions)
OO |
| (1) | Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G. |
| (2) | Consists of (i) 1,708,850 shares of common stock and 389,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by Venrock Healthcare Capital Partners III, L.P.; (ii) 170,950 shares of common stock and 39,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,620,200 shares of common stock and 1,052,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon conversion of the Series A Preferred Stock held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Securities Purchase Agreement dated as of June 22, 2023, the Issuer may not effect the conversion of any such Series A Preferred Stock and a holder will not be entitled to convert any portion of such Series A Preferred Stock, if, upon giving effect to such conversion, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the conversion. |
| CUSIP No. 00773J103 | Page 11 of 24 |
| (3) | This percentage is calculated based upon the sum of (i) 65,395,159 shares of common stock outstanding as of May 2, 2023 as reported in the Form 10-Q filed by the Issuer on May 11, 2023; (ii) 13,013,636 shares of common stock issued in connection with the merger transaction disclosed in the Issuer’s Current Report on Form 8-K filed on June 23, 2023; and (iii) 1,480,000 shares of common stock issuable upon the conversion of Series A Preferred Stock described in Footnote 2 above. |
| CUSIP No. 00773J103 | Page 12 of 24 |
| 1. | Names of Reporting Persons
Shah, Nimish |
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)
(a) x (1) (b) ¨ |
| 3. | SEC Use Only
|
| 4. | Citizenship or Place of Organization
United States |
Number of Shares Beneficially Owned by Each Reporting Person With | 5. | Sole Voting Power
0 |
| 6. | Shared Voting Power
7,980,000 (2) | |
| 7. | Sole Dispositive Power
0 | |
| 8. | Shared Dispositive Power
7,980,000 (2) |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
7,980,000 (2) |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
|
| 11. | Percent of Class Represented by Amount in Row (9)
9.99% (3) |
| 12. | Type of Reporting Person (See Instructions)
IN |
| (1) | Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G. |
| (2) | Consists of (i) 1,708,850 shares of common stock and 389,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by Venrock Healthcare Capital Partners III, L.P.; (ii) 170,950 shares of common stock and 39,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,620,200 shares of common stock and 1,052,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon conversion of the Series A Preferred Stock held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Securities Purchase Agreement dated as of June 22, 2023, the Issuer may not effect the conversion of any such Series A Preferred Stock and a holder will not be entitled to convert any portion of such Series A Preferred Stock, if, upon giving effect to such conversion, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the conversion. |
| CUSIP No. 00773J103 | Page 13 of 24 |
| (3) | This percentage is calculated based upon the sum of (i) 65,395,159 shares of common stock outstanding as of May 2, 2023 as reported in the Form 10-Q filed by the Issuer on May 11, 2023; (ii) 13,013,636 shares of common stock issued in connection with the merger transaction disclosed in the Issuer’s Current Report on Form 8-K filed on June 23, 2023; and (iii) 1,480,000 shares of common stock issuable upon the conversion of Series A Preferred Stock described in Footnote 2 above. |
| CUSIP No. 00773J103 | Page 14 of 24 |
| 1. | Names of Reporting Persons
Koh, Bong |
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)
(a) x (1) (b) ¨ |
| 3. | SEC Use Only
|
| 4. | Citizenship or Place of Organization
United States |
Number of Shares Beneficially Owned by Each Reporting Person With | 5. | Sole Voting Power
0 |
| 6. | Shared Voting Power
7,980,000 (2) | |
| 7. | Sole Dispositive Power
0 | |
| 8. | Shared Dispositive Power
7,980,000 (2) |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
7,980,000 (2) |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
|
| 11. | Percent of Class Represented by Amount in Row (9)
9.99% (3) |
| 12. | Type of Reporting Person (See Instructions)
IN |
| (1) | Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G. |
| (2) | Consists of (i) 1,708,850 shares of common stock and 389,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by Venrock Healthcare Capital Partners III, L.P.; (ii) 170,950 shares of common stock and 39,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,620,200 shares of common stock and 1,052,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon conversion of the Series A Preferred Stock held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Securities Purchase Agreement dated as of June 22, 2023, the Issuer may not effect the conversion of any such Series A Preferred Stock and a holder will not be entitled to convert any portion of such Series A Preferred Stock, if, upon giving effect to such conversion, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the conversion. |
| CUSIP No. 00773J103 | Page 15 of 24 |
| (3) | This percentage is calculated based upon the sum of (i) 65,395,159 shares of common stock outstanding as of May 2, 2023 as reported in the Form 10-Q filed by the Issuer on May 11, 2023; (ii) 13,013,636 shares of common stock issued in connection with the merger transaction disclosed in the Issuer’s Current Report on Form 8-K filed on June 23, 2023; and (iii) 1,480,000 shares of common stock issuable upon the conversion of Series A Preferred Stock described in Footnote 2 above. |
| CUSIP No. 00773J103 | Page 16 of 24 |
| Item 1. | ||
| (a) | Name of Issuer
Aeglea BioTherapeutics, Inc. | |
| (b) | Address of Issuer’s Principal Executive Offices
805 Las Cimas Parkway, Suite 100, Austin, TX 78746 | |
| Item 2. | ||
| (a) | Name of Person Filing
Venrock Healthcare Capital Partners III, L.P. VHCP Co-Investment Holdings III, LLC Venrock Healthcare Capital Partners EG, L.P. VHCP Management III, LLC VHCP Management EG, LLC Nimish Shah Bong Koh | |
| (b) | Address of Principal Business Office or, if none, Residence | ||
| New York Office: | Palo Alto Office: | ||
| 7 Bryant Park | 3340 Hillview Avenue | ||
| 23rd Floor | Palo Alto, CA 94304 | ||
| New York, NY 10018 | |||
| (c) | Citizenship
All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens. | |
| (d) | Title of Class of Securities
Common Stock, $0.0001 par value per share | |
| (e) | CUSIP Number
00773J103 | |
| Item 3. | If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
| Not applicable | ||
| CUSIP No. 00773J103 | Page 17 of 24 |
| Item 4. | Ownership | ||
| (a) | Amount beneficially owned: | ||
| Venrock Healthcare Capital Partners III, L.P. | 7,980,000 (1) | ||
| VHCP Co-Investment Holdings III, LLC | 7,980,000 (1) | ||
| Venrock Healthcare Capital Partners EG, L.P. | 7,980,000 (1) | ||
| VHCP Management III, LLC | 7,980,000 (1) | ||
| VHCP Management EG, LLC | 7,980,000 (1) | ||
| Nimish Shah | 7,980,000 (1) | ||
| Bong Koh | 7,980,000 (1) | ||
| (b) | Percent of class: | ||
| Venrock Healthcare Capital Partners III, L.P. | 9.99% (2) | ||
| VHCP Co-Investment Holdings III, LLC | 9.99% (2) | ||
| Venrock Healthcare Capital Partners EG, L.P. | 9.99% (2) | ||
| VHCP Management III, LLC | 9.99% (2) | ||
| VHCP Management EG, LLC | 9.99% (2) | ||
| Nimish Shah | 9.99% (2) | ||
| Bong Koh | 9.99% (2) | ||
| (c) | Number of shares as to which the person has: | ||
| (i) Sole power to vote or to direct the vote: | |||
| Venrock Healthcare Capital Partners III, L.P. | 0 | ||
| VHCP Co-Investment Holdings III, LLC | 0 | ||
| Venrock Healthcare Capital Partners EG, L.P. | 0 | ||
| VHCP Management III, LLC | 0 | ||
| VHCP Management EG, LLC | 0 | ||
| Nimish Shah | 0 | ||
| Bong Koh | 0 | ||
| (ii) Shared power to vote or to direct the vote: | |||
| Venrock Healthcare Capital Partners III, L.P. | 7,980,000 (1) | ||
| VHCP Co-Investment Holdings III, LLC | 7,980,000 (1) | ||
| Venrock Healthcare Capital Partners EG, L.P. | 7,980,000 (1) | ||
| VHCP Management III, LLC | 7,980,000 (1) | ||
| VHCP Management EG, LLC | 7,980,000 (1) | ||
| Nimish Shah | 7,980,000 (1) | ||
| Bong Koh | 7,980,000 (1) | ||
| CUSIP No. 00773J103 | Page 18 of 24 |
| (iii) Sole power to dispose or to direct the disposition of: | |||
| Venrock Healthcare Capital Partners III, L.P. | 0 | ||
| VHCP Co-Investment Holdings III, LLC | 0 | ||
| Venrock Healthcare Capital Partners EG, L.P. | 0 | ||
| VHCP Management III, LLC | 0 | ||
| VHCP Management EG, LLC | 0 | ||
| Nimish Shah | 0 | ||
| Bong Koh | 0 | ||
| (iv) Shared power to dispose or to direct the disposition of: | |||
| Venrock Healthcare Capital Partners III, L.P. | 7,980,000 (1) | ||
| VHCP Co-Investment Holdings III, LLC | 7,980,000 (1) | ||
| Venrock Healthcare Capital Partners EG, L.P. | 7,980,000 (1) | ||
| VHCP Management III, LLC | 7,980,000 (1) | ||
| VHCP Management EG, LLC | 7,980,000 (1) | ||
| Nimish Shah | 7,980,000 (1) | ||
| Bong Koh | 7,980,000 (1) | ||
| (1) Consists of (i) 1,708,850 shares of common stock and 389,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by Venrock Healthcare Capital Partners III, L.P.; (ii) 170,950 shares of common stock and 39,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,620,200 shares of common stock and 1,052,000 shares of common stock issuable upon conversion of Series A Preferred Stock held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon conversion of the Series A Preferred Stock held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Securities Purchase Agreement dated as of June 22, 2023, the Issuer may not effect the conversion of any such Series A Preferred Stock and a holder will not be entitled to convert any portion of such Series A Preferred Stock, if, upon giving effect to such conversion, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the conversion. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.
(2) This percentage is calculated based upon the sum of (i) 65,395,159 shares of common stock outstanding as of May 2, 2023 as reported in the Form 10-Q filed by the Issuer on May 11, 2023; (ii) 13,013,636 shares of common stock issued in connection with the merger transaction disclosed in the Issuer’s Current Report on Form 8-K filed on June 23, 2023; and (iii) 1,480,000 shares of common stock issuable upon the conversion of Series A Preferred Stock described in Footnote 1 above. |
| CUSIP No. 00773J103 | Page 19 of 24 |
| Item 5. | Ownership of Five Percent or Less of a Class |
| If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐ | |
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person |
| Not applicable | |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person |
| Not applicable | |
| Item 8. | Identification and Classification of Members of the Group |
| Not applicable | |
| Item 9. | Notice of Dissolution of Group |
| Not applicable | |
| Item 10. | Certification |
| By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect. | |
| CUSIP No. 00773J103 | Page 20 of 24 |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: July 10, 2023
| Venrock Healthcare Capital Partners III, L.P. | Venrock Healthcare Capital Partners EG, L.P. | |||
| By: | VHCP Management III, LLC | By: | VHCP Management EG, LLC | |
| Its: | General Partner | Its: | General Partner | |
| By: | /s/ Sherman G. Souther | By: | /s/ Sherman G. Souther | |
| Name: Sherman G. Souther | Name: Sherman G. Souther | |||
| Its: Authorized Signatory | Its: Authorized Signatory | |||
| VHCP Co-Investment Holdings III, LLC | ||||
| By: | VHCP Management III, LLC | |||
| Its: | Manager | |||
| By: | /s/ Sherman G. Souther | |||
| Name: Sherman G. Souther | ||||
| Its: Authorized Signatory | ||||
| VHCP Management III, LLC | VHCP Management EG, LLC | |||
| By: | /s/ Sherman G. Souther | By: | /s/ Sherman G. Souther | |
| Name: Sherman G. Souther | Name: Sherman G. Souther | |||
| Its: Authorized Signatory | Its: Authorized Signatory | |||
| Nimish Shah | ||||
| /s/ Sherman G. Souther | ||||
| Sherman G. Souther, Attorney-in-fact | ||||
| Bong Koh | ||||
| /s/ Sherman G. Souther | ||||
| Sherman G. Souther, Attorney-in-fact | ||||
| CUSIP No. 00773J103 | Page 21 of 24 |
EXHIBITS
A: Joint Filing Agreement
B: Power of Attorney for Nimish Shah
C: Power of Attorney for Bong Koh
| CUSIP No. 00773J103 | Page 22 of 24 |
EXHIBIT A
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Aeglea BioTherapeutics, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 10th day of July, 2023.
| Venrock Healthcare Capital Partners III, L.P. | Venrock Healthcare Capital Partners EG, L.P. | |||
| By: | VHCP Management III, LLC | By: | VHCP Management EG, LLC | |
| Its: | General Partner | Its: | General Partner | |
| By: | /s/ Sherman G. Souther | By: | /s/ Sherman G. Souther | |
| Name: Sherman G. Souther | Name: Sherman G. Souther | |||
| Its: Authorized Signatory | Its: Authorized Signatory | |||
| VHCP Co-Investment Holdings III, LLC | ||||
| By: | VHCP Management III, LLC | |||
| Its: | Manager | |||
| By: | /s/ Sherman G. Souther | |||
| Name: Sherman G. Souther | ||||
| Its: Authorized Signatory | ||||
| VHCP Management III, LLC | VHCP Management EG, LLC | |||
| By: | /s/ Sherman G. Souther | By: | /s/ Sherman G. Souther | |
| Name: Sherman G. Souther | Name: Sherman G. Souther | |||
| Its: Authorized Signatory | Its: Authorized Signatory | |||
| Nimish Shah | ||||
| /s/ Sherman G. Souther | ||||
| Sherman G. Souther, Attorney-in-fact | ||||
| Bong Koh | ||||
| /s/ Sherman G. Souther | ||||
| Sherman G. Souther, Attorney-in-fact | ||||
| CUSIP No. 00773J103 | Page 23 of 24 |
EXHIBIT B
POWER OF ATTORNEY FOR NIMISH SHAH
KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:
| (i) | prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and |
| (ii) | take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion. |
The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.
This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 10th day of July, 2023.
| /s/ Nimish Shah |
| CUSIP No. 00773J103 | Page 24 of 24 |
EXHIBIT C
POWER OF ATTORNEY FOR BONG KOH
KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:
| (i) | prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and |
| (ii) | take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion. |
The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.
This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 10th day of July, 2023.
| /s/ Bong Koh |